ClinicalTrials.gov
public full text
Public Domain
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- HNSCC Immuno-genomics Project#870613
- Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma#1057364
- Immune Therapy of HPV-induced Cancers#1229555
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer#826962
- Impact of surgical approaches on prognosis in elderly patients with T4N0M0 non-small cell lung cancer: a competing risk analysis based on the SEER database.#685579
Record · ID 1262315
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive